IceCure Medical Ltd (ICCM) Earnings Call Transcript
November 19, 2025
Earnings Call Speaker Segments
Thank you, Ella. Hello everyone, and thanks for joining IceCure Medical's conference call. Today we'll review our financial results for the nine-month period that concluded on September 30, 2025, and we'll also bring you up to speed on some recent operational developments. The earnings press release went out earlier this morning, so please take a look at that. Joining us today are Eyal Shamir, IceCure Medical's CEO, and Ronen Tsimerman, our CFO. Before we dive in, I'd like to briefly read a note about forward-looking statements. This call, including the Q&A portion that comes afterward, contains forward-looking statements as defined by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with other federal securities laws. Phrases such as expects, anticipates, intends, plans, believes, seeks, estimates, along with comparable wording or forms of those terms, serve to flag forward-looking statements. As an example, forward-looking statements are being used in this presentation when we discuss the FDA marketing authorization of ProSense fueling significant growth for us and enabling wider action on behalf of patients. Also included are the belief that adoption internationally will be backed by global interest resulting from the FDA authorization, and the belief that within the U.S., ProSense will stand as the sole cleared cryoablation system. Regarding breast cancer for the near term, the anticipation that Terumo Corporation will file for regulatory approval of ProSense in Japan during the first six months of 2026, the possibility that revenue along with gross profits could keep fluctuating from one quarter to another as the company concentrates on establishing sales at commercial scale, and the conviction that its holdings of cash, cash equivalents, and short-term deposits leave it financially better situated to keep carrying out regulatory, clinical, and commercial efforts. During today's call, anything we say that looks ahead involves additional risks and unknowns. A lot of those sit outside the company's ability to influence. You can find them listed in the risk factor portion of our annual report on Form 20F covering the year that wrapped up on December 31, 2024. That document was submitted to the Securities and Exchange Commission on March 27, 2025, and it's posted on the SEC's site, www.sec.gov. As for any plan or duty to refresh or amend forward-looking statements — whether triggered by fresh information, upcoming occurrences, or something else — the company lays out its position on that. Keep in mind this call carries information that's time-sensitive and reflects only what we know as of the live broadcast happening today, November 19, 2025. We also want to note that on today's call, some figures we mention are non-GAAP metrics. For those, please see the reconciliation tables and additional details regarding these non-GAAP metrics in the earnings press release we put out earlier today. At this point, I'll hand things over to IceCure Medical's CEO, Eyal Shamir. Eyal, the floor is yours.
Thank you, Michael, and greetings to everyone, and I appreciate you being with us today as we go over what we achieved in the opening nine months of 2025. Throughout Q3, we stayed dedicated and carried out work on several fronts, among them commercial activities, technology, intellectual property, and regulatory affairs. In October, we shared news of the single most important milestone since IceCure Medical began, which was the FDA's decision to grant marketing authorization for our ProSense cryoablation system for treating low-risk breast cancer; that green light confirms the clinical investigation we have funded across many years and puts IceCure Medical leading the way in minimally invasive care for breast cancer. To reiterate, this clearance applies to women who are 70 or older, whose tumors measure no more than 1.5 centimeters, and who are on adjuvant endocrine therapy, and it also includes women unable to have surgery. This indication spans a group of about 46,000 women in the U.S. who are above age 70 and receive a diagnosis annually, along with an estimated 88,000 patients who either cannot or will not undergo surgery, plus patients treatable for palliative reasons. By serving the needs of patients who cannot or opt not to have surgery, ProSense delivers a valuable option for treating cancer that those individuals previously could not access. On top of that, 10% of women each year receive a diagnosis of benign breast tumors, and among them, roughly 63,000 women in the U.S. undergo an operation to take out those benign breast tumors through a surgical procedure known as lumpectomy. Taken together, this adds up to a substantial addressable market for ProSense of approximately 200,000 patients per year, which means a considerable opportunity lies ahead for IceCure. Feedback to the FDA's decision has been highly positive; we are experiencing rising interest from clinicians in the U.S., among them breast surgeons, interventional radiologists, and breast radiologists, a large number of whom are asking for demonstrations and installations. Our commercial team in the U.S. is concentrating on broadening ProSense installations, printing volume, and usage. We think IceCure is favorably situated right now for reasons that include the fact that the FDA marketing authorization made clear that any other firm hoping to submit a 510(k) marketing authorization for a separate cryoablation system to treat breast cancer must provide five years of follow-up data, employ a liquid nitrogen-based system, and use probes of 10 gauge. Based on what we know, no other company is presently running a breast cryoablation study inside the U.S. Because of this substantial barrier to entry, we expect ProSense will be the sole cryoablation cleared in the U.S. for breast cancer for the foreseeable future. Within the U.S., we have more than 20 commercial sites using ProSense before the FDA marketing authorization; we anticipate that the count of commercial sites will grow organically, on top of the 30 clinical sites planned for our forthcoming post-market study. We have handed the study design to the FDA for review and will share an update once we get the FDA approvals needed to proceed with the post-market study. To remind everyone, the FDA clearance to relocate — pardon me, to remind everyone, the clinical site, while it treats patients enrolled in studies and receives reimbursement, will likewise be open to suitable patients pursuing ProSense cryoablations on a commercial basis. We anticipate this launch will generate substantial expansion in both clinical utilization and product uptake. At present, ProSense gains from a CPT-3 code that covers roughly $3,800 in facility cost. That figure should rise to slightly above $4,000 at the start of January 2026. This enhancement, together with the FDA authorization, ought to enable wider patient access. Outside America, we are seeing considerable worldwide enthusiasm from clinicians reacting to the FDA decision in markets where ProSense already holds approval for breast cancer. Only a few days back, Switzerland joined the expanding roster of nations where ProSense has received approval. At our Israel office, we are right now hosting a visit from a notable Brazilian medical delegation. Their visit included a clinical overview along with a roundtable discussion involving meetings with key opinion leaders and a presentation concerning an ongoing clinical trial for breast cryoablation. The delegation, made up of five interventional radiologists and breast surgeons, additionally watched live clinical cases at Nate Sion and Bailey Medical Centers in Israel. In Brazil, South America's biggest healthcare market, ProSense is approved for breast cancer along with other indications, and we hold a distribution agreement with $6.6 million in sales anticipated across the coming five years. Moreover, our global marketing and clinical team has been contacted by many medical societies to secure our involvement in conferences taking place in 2026. European and Asian medical societies are specifically introducing breast cancer cryoablation master classes featuring ProSense. On the innovation side, we keep achieving solid progress. In September 2025, our next generation cryoablation system obtained regulatory approval in Israel for breast cancer and additional indications. We lately obtained a notice of patent allowance for Accent and its cryo probe in the U.S. and in Japan, further reinforcing the intellectual property portfolio. ProSense went on gaining notable visibility at major medical conferences worldwide. Since the third quarter began, it appeared at CIRSA 2025, the Japanese Breast Cancer Society Conference, the European Society of Breast Imaging Congress, and the Aptitude Health Stakeholder Leadership in the Breast Cancer Care Field Summit in New Orleans; beyond that, we have teamed up with Carigi Hospital in Florence, Italy, and ran a two-day course of theoretical and hands-on training for physicians from throughout the world, helping to widen adoption and expertise for breast cancer cryoablation. Lastly, ongoing clinical validation keeps reinforcing the safety and the effectiveness of our technology. During and after the close of the third quarter by itself, 13 independent studies in breast cancer were presented and published, plus encouraging data in lung cancer and endometriosis, further showing the versatility and clinical value of ProSense; alongside the recent approval in Switzerland, we are also pushing forward our global regulatory strategy. Terumo Corporation, our Japanese partner, had intended to file for regulatory clearance for ProSense as a breast cancer therapy during the opening six months of 2026 — a significant move that widens availability of ProSense into additional global markets. To sum up, IceCure is, in our view, stepping into a thrilling period of expansion. Our sales and marketing approach is being rolled out across the U.S., aimed at roughly 200,000 women each year as the patient group. To generate and speed up that growth, we'll keep building out clinical evidence, enhancing reimbursement, and moving into fresh markets. Regarding what lies ahead, we have conviction on behalf of both patients and shareholders. At this point I'll hand the call over to Ronen.
Thanks, Eyal. Looking at the nine months that closed on September 30, 2025, we brought in $2.1 million of revenue, versus $2.4 million during the matching stretch of 2024. Within the first nine months of 2024, $100,000 came from the exclusive distribution agreement we have with Terumo, our Japanese distributor, along with other services, whereas during the first nine months of 2025 we recorded no Terumo revenue at all. Sales fell by $316,000 across the nine months ended September 30, 2025, driven by lower sales in Japan, elsewhere in Asia, and North America, though growth in Latin America partly made up for that. As we've noted before, quarterly revenue will likely swing around as commercial activity builds both in the U.S. and worldwide now that the FDA has granted marketing clearance for ProSense in low-risk breast cancer. Gross profit for the nine months ended September 30, 2025, came to $626,000, against $1,034,000 in the comparable prior-year period. That works out to a gross margin of 30%, down from 43% during the same period in 2024. Like we've said previously, gross profit may keep fluctuating from quarter to quarter while the company concentrates on scaling up commercial sales. On the whole, total operating expenses shrank to $11.5 million for the nine months ended September 30, 2025, from $12.2 million a year earlier. That shows how we're working to streamline spending while still delivering on commercial and regulatory fronts. Our net loss for the nine months ended September 30, 2025, stood at $10.8 million, or $0.18 per share, roughly in line with the $10 million, or $0.22, net loss posted in the same period last year. At September 30, 2025, cash equivalents and short-term deposits totaled $10 million, up from $7.6 million at December 31, 2024. Back in July 2025, we wrapped up a rights offering that drew roughly two times the subscription needed, generating $10 million in gross proceeds to back commercialization of the ProSense system. Over the first 10 months of 2025, we brought in about $5.87 million in net proceeds by selling 5.4 million ordinary shares via an at-the-market offering facility. That lifted our cash balance to $11.8 million as of October 31, 2025. We think this leaves us financially stronger to keep pushing forward on our regulatory, clinical, and commercial initiatives. Operator, let's open the call for Q&A now.
Thanks, Eyal and Ronen. I'd simply like to learn the current status regarding FDA clearance for that post-market study. I understand you're still waiting on the final green light. Have you heard anything from them at all, or are you basically just waiting to see how things play out?
Morning, Anthony. Hello there. Like I explained during my section, the protocol went to the FDA, and we began back-and-forth dialogue with them so it could be finalized; however, the formal protocol, together with every other component, has already been delivered to the FDA.
All right. So no indication has been given by them, and there isn't really a set timeline for the official sign-off, as far as we know. That said, you've pinpointed 30 sites, and yes, 30 sites are what's required. From what I recall, during the previous quarter, you mentioned that 20 had already been identified. Could you update us on where those figures stand now?
Yes. Roughly 20 sites have been identified on our end. We're continuing to add to that number, though the main focus is on the clinical protocol, the statistical analysis plan, and the claim database. So all of these elements are being worked on; and my sense is that roughly by year-end — perhaps things slip a little because of the shutdown — but by year-end, or very early into next year, the final approval should come through; and then come summer 2026, we'll need to — or possibly sooner, though no later than summer 2026 — we'll need to enroll the first patient, 20%, which works out to 80 patients by the close of 2026.
That really sounds like a pretty simple bar to clear. In the press release, you noted there could be a larger group of patients who stand to gain from cryoablation, since those who are low risk and above 70 were, I believe, initially pegged at roughly 46,000. Yet the release stated an extra 88,000 patients might benefit, plus another 63,000 who could be treated for benign tumors too. Is this something new? Could you expand on it a bit? Thanks.
Yes. Anthony, as you may recall, our FDA authorization letter had two components. The first covers low-risk early stage disease in patients 70 and older, up to 1.5 centimeters. As you said, that works out to roughly 46,000 new U.S. patients annually. The second component, which stems from the breakthrough device designation IceCure received in 2021, covers patients unsuitable for surgery — perhaps those with comorbidities making it impossible to bring them into the OR and place them under general anesthesia, those unwilling to undergo surgery, or those whose disease may be less curable and who are treated more for palliation. Based on all the evidence from CIRSE and elsewhere, we estimate 88,000 new U.S. patients annually fall into the nonsurgical or unwilling category. Then there are benign breast tumors, which now bring in our new users. The biggest driver, naturally, is breast cancer. But those hospitals, clinics, breast surgeons, and breast radiologists also see younger patients — again, 1 million new patients each year, mostly between ages 21 and 35, dealing with benign tumors, and roughly 63,000 of those undergo surgical removal. So we think a portion of this addressable market could be taken over by cryoablation as a minimally invasive option, because for those younger patients, body image and the bikini line matter enormously. The outpatient facility fee coverage is identical, and in January it will come to about $4,000. For that, we have a dedicated indication and even a specific CPT-1 code for benign breast tumors. All of this adds up to a potential addressable market exceeding 200,000 new patients annually in the U.S. alone.
We appreciate you being on the call with us today and for the excellent questions. In our view, the marketing authorization from the FDA has significantly altered the path of our growth. As we keep carrying out our commercial rollout of ProSense across the U.S. and around the world, we’re eager to keep all of you informed. Enjoy the rest of your day, everyone, and to those of you in the U.S., enjoy a happy Thanksgiving. Thanks.
That brings us to the end of the IceCure conference call covering results for the third quarter of 2025. We appreciate everyone for joining. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IceCure Medical Ltd transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IceCure Medical Ltd earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.